140 related articles for article (PubMed ID: 27561697)
21. Colonic EBV-Associated Lymphoproliferative Disorder in a Patient Treated with Rabbit Antithymocyte Globulin for Aplastic Anemia.
Sugimoto-Sekiguchi H; Tashiro H; Shirasaki R; Arai T; Yamamoto T; Oka Y; Akiyama N; Kawasugi K; Shirafuji N
Case Rep Gastrointest Med; 2012; 2012():395801. PubMed ID: 23050175
[TBL] [Abstract][Full Text] [Related]
22. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
Coppoletta S; Tedone E; Galano B; Soracco M; Raiola AM; Lamparelli T; Gualandi F; Bregante S; Ibatici A; di Grazia C; Dominietto A; Varaldo R; Bruno B; Frassoni F; Van Lint MT; Bacigalupo A
Biol Blood Marrow Transplant; 2011 Jun; 17(6):901-7. PubMed ID: 20950702
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab.
Patriarca F; Medeot M; Isola M; Battista ML; Sperotto A; Pipan C; Toffoletti E; Dozzo M; Michelutti A; Gregoraci G; Geromin A; Cerno M; Savignano C; Rinaldi C; Barbone F; Fanin R
Transpl Infect Dis; 2013 Jun; 15(3):259-67. PubMed ID: 23405972
[TBL] [Abstract][Full Text] [Related]
24. [A Case of Severe Chronic Active Epstein-Barr Virus Infection with Aplastic Anemia and Hepatitis].
Lee JI; Lee SW; Han NI; Ro SM; Noh YS; Jang JW; Bae SH; Choi JY; Yoon SK
Korean J Gastroenterol; 2016 Jan; 67(1):39-43. PubMed ID: 26809631
[TBL] [Abstract][Full Text] [Related]
25. [Quantitative monitoring of mononucleated cell Epstein-Barr virus (EBV)-DNA for predicting EBV associated lymphoproliferative disorders after stem cell transplantation.].
Wang LH; Ren HY; Sun YH; Qiu ZX; Cen XN; Ou JP; Xu WL; Wang MJ; Wang WS; Li Y; Dong YJ; Yin Y; Liang ZY
Zhonghua Xue Ye Xue Za Zhi; 2010 Feb; 31(2):73-6. PubMed ID: 20302791
[TBL] [Abstract][Full Text] [Related]
26. High fatality rate of Epstein-Barr virus-associated lymphoproliferative disorder occurring after bone marrow transplantation with rabbit antithymocyte globulin conditioning regimens.
Peres E; Savasan S; Klein J; Abidi M; Dansey R; Abella E
J Clin Microbiol; 2005 Jul; 43(7):3540-3. PubMed ID: 16000501
[TBL] [Abstract][Full Text] [Related]
27. B-Cell-Rich T-Cell Lymphoma Associated with Epstein-Barr Virus-Reactivation and T-Cell Suppression Following Antithymocyte Globulin Therapy in a Patient with Severe Aplastic Anemia.
Hanaoka N; Murata S; Hosoi H; Shimokado A; Mushino T; Kuriyama K; Hatanaka K; Nishikawa A; Kurimoto M; Sonoki T; Muragaki Y; Nakakuma H
Hematol Rep; 2015 Sep; 7(3):5906. PubMed ID: 26487932
[TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?
Solano C; Mateo EM; Pérez A; Talaya A; Terol MJ; Albert E; Giménez E; Vinuesa V; Piñana JL; Boluda JCH; Navarro D
J Clin Virol; 2017 Dec; 97():26-32. PubMed ID: 29096390
[TBL] [Abstract][Full Text] [Related]
29. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.
Carpenter B; Haque T; Dimopoulou M; Atkinson C; Roughton M; Grace S; Denovan S; Fielding A; Kottaridis PD; Griffiths P; Mackinnon S; Emery V; Chakraverty R
Transplantation; 2010 Sep; 90(5):564-70. PubMed ID: 20555307
[TBL] [Abstract][Full Text] [Related]
30. EBV-induced lymphoproliferative disorders in rheumatic patients: A systematic review of the literature.
Berti A; Felicetti M; Peccatori S; Bortolotti R; Guella A; Vivaldi P; Morelli L; Barabareschi M; Paolazzi G
Joint Bone Spine; 2018 Jan; 85(1):35-40. PubMed ID: 28196776
[TBL] [Abstract][Full Text] [Related]
31. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
[TBL] [Abstract][Full Text] [Related]
32. Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.
Kobayashi S; Sano H; Mochizuki K; Ohara Y; Takahashi N; Ohto H; Kikuta A
Pediatr Int; 2017 Sep; 59(9):973-978. PubMed ID: 28581032
[TBL] [Abstract][Full Text] [Related]
33. Concurrent Epstein-Barr virus associated NK/T cell lymphoma after immunosuppressive therapy for aplastic anemia: report of a case and review of literature.
Yin G; Ni Y; Xiao Z; He G; Miao K
Int J Clin Exp Pathol; 2015; 8(6):7588-93. PubMed ID: 26261674
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr Virus-Induced Post-Transplant Lymphoproliferative Disorder of the Central Nervous System Successfully Treated with Chemo-immunotherapy.
Inoue H; Rai S; Tanaka H; Espinoza JL; Komori-Inoue M; Kakutani H; Minamoto S; Kumode T; Nakayama S; Taniguchi Y; Morita Y; Okuda T; Tatsumi Y; Ashida T; Matsumura I
Viruses; 2020 Apr; 12(4):. PubMed ID: 32276450
[TBL] [Abstract][Full Text] [Related]
35. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
[TBL] [Abstract][Full Text] [Related]
36. An unexpectedly high incidence of Epstein-Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma.
Powell JL; Bunin NJ; Callahan C; Aplenc R; Griffin G; Grupp SA
Bone Marrow Transplant; 2004 Mar; 33(6):651-7. PubMed ID: 14730339
[TBL] [Abstract][Full Text] [Related]
37. Amegakaryocytic Thrombocytopenia and Subsequent Aplastic Anemia Associated with Apparent Epstein-Barr Virus Infection.
Levy I; Laor R; Jiries N; Bejar J; Polliack A; Tadmor T
Acta Haematol; 2018; 139(1):7-11. PubMed ID: 29301129
[TBL] [Abstract][Full Text] [Related]
38. Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation.
Meyer SC; Medinger M; Halter JP; Baldomero H; Hirsch HH; Tzankov A; Dirnhofer S; Passweg JR; Tichelli A
Hematology; 2014 Jul; 19(5):280-5. PubMed ID: 24074746
[TBL] [Abstract][Full Text] [Related]
39. [Successful donor lymphocyte infusion for Epstein-Barr virus-associated lymphoproliferative disorder after allogeneic bone marrow transplantation from an HLA 1-locus-mismatched sibling donor in a patient with acute lymphocytic leukemia].
Yago K; Itoh M; Shimada H
Rinsho Ketsueki; 2001 Nov; 42(11):1105-10. PubMed ID: 11808079
[TBL] [Abstract][Full Text] [Related]
40. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation.
McGuirk JP; Seropian S; Howe G; Smith B; Stoddart L; Cooper DL
Bone Marrow Transplant; 1999 Dec; 24(11):1253-8. PubMed ID: 10642818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
